Hanming Wang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Hanming Wang has a total of 28 co-authors. Here are the top co-authors by number of shared publications:
- Yang Bai
Department of Clinical Pharmacology, School of Pharmacy, China Medical University, Shenyang, China
2 shared publications - Yun Wang
Department of Clinical Pharmacology, School of Pharmacy China Medical University Shenyang China
2 shared publications - Bing-Xing Pan
Department of Pathology, The First Affiliated Hospital and Institute of Biomedical Innovation, School of Basic Medical Sciences, Jiangxi Medical College, Nanchang University, Nanchang, China
1 shared publication Chun Song
Laboratory of Nucleic Acid Technology, Institute of Molecular Medicine, Peking University, Beijing, 100871, China
1 shared publication- Chun Song
Department of Gastrointestinal Surgery
1 shared publication - Guo-Huang Fan
Excecutive Office, Immunophage Biotech Co., Ltd., Shanghai, China
1 shared publication
Latest Publications
- 1 October 2021
- Published by Elsevier in Archives of Biochemistry and Biophysics
- Vol. 711, 109023
m6A-seq analysis of microRNAs reveals that the N6-methyladenosine modification of miR-21–5p affects its target expression
- 1 October 2021
- Published by Elsevier in Archives of Biochemistry and Biophysics
- Vol. 711, 109023
m6A-seq analysis of microRNAs reveals that the N6-methyladenosine modification of miR-21–5p affects its target expression
- Open Access
- 1 December 2018
- Published by Wolters Kluwer Health in Journal of the Chinese Medical Association
- Vol. 81 (12) , 1077-1087
Involvement of S100A4/Mts1 and associated proteins in the protective effect of fluoxetine against MCT – Induced pulmonary hypertension in rats
Pulmonary arterial hypertension (PAH) is a complex pulmonary vasculature disease characterized by remodeling of the pulmonary vessels and a persistent increase in the pulmonary vascular resistance (PVR) with a poor prognosis. Serotonin increases the expression of S100A4/Mts1, which in turn stimulates the proliferation and migration of human pulmonary artery smooth muscle cells through the interaction with RAGE (receptor for advanced glycation end products) and thus S100A4/Mts1 has been implicated in the development of PAH in vitro. Fluoxetine, a selective serotonin re-uptake inhibitor has been shown to protect against PAH. The current study was designed to test whether S100A4 and its associated proteins connected in the development of PAH in vivo as well as to investigate the involvement of those proteins in the protective effect of fluoxetine against PAH. MCT-induced PAH models were established in Wistar rats by a single intraperitoneal injection of MCT (60 mg/kg). Fluoxetine (2 and 10 mg/kg/day) was intragastrically administered once a day for 3 weeks along with controls. The detection methods followed include Hematoxylin and Eosin (H&E) staining, immunohistochemistry, western blotting and real-time reverse transcription-polymerase chain reaction (RT-PCR). MCT induced pulmonary hypertension, pulmonary vascular remodeling, and right ventricular hypertrophy significantly increased the expressions of S100A4 and RAGE in the pulmonary arteries, lungs and right ventricle (RV). Fluoxetine dose-dependently inhibited MCT-induced pulmonary arterial hypertension, pulmonary vascular remodeling, and right ventricular hypertrophy and reduced the S100A4 and RAGE. Further analysis revealed that fluoxetine alleviated both the increase of p53, MMP13, MMP2 and MMP9 and the decrease of pp53Ser15 and MDM2 in lungs and RV tissues of MCT-induced PAH rats. From the present investigation it could be concluded that S100A4/Mts1 and its associated proteins are involved in the evolution of MCT-induced PAH in rats and fluoxetine inhibits MCT-induced PAH in rats mainly through S100A4/RAGE signaling axis and involved factors.
- 1 December 2018
- Published by Wolters Kluwer Health in Journal of the Chinese Medical Association
- Vol. 81 (12) , 1077-1087
Open AccessInvolvement of S100A4/Mts1 and associated proteins in the protective effect of fluoxetine against MCT – Induced pulmonary hypertension in rats
Pulmonary arterial hypertension (PAH) is a complex pulmonary vasculature disease characterized by remodeling of the pulmonary vessels and a persistent increase in the pulmonary vascular resistance (PVR) with a poor prognosis. Serotonin increases the expression of S100A4/Mts1, which in turn stimulates the proliferation and migration of human pulmonary artery smooth muscle cells through the interaction with RAGE (receptor for advanced glycation end products) and thus S100A4/Mts1 has been implicated in the development of PAH in vitro. Fluoxetine, a selective serotonin re-uptake inhibitor has been shown to protect against PAH. The current study was designed to test whether S100A4 and its associated proteins connected in the development of PAH in vivo as well as to investigate the involvement of those proteins in the protective effect of fluoxetine against PAH. MCT-induced PAH models were established in Wistar rats by a single intraperitoneal injection of MCT (60 mg/kg). Fluoxetine (2 and 10 mg/kg/day) was intragastrically administered once a day for 3 weeks along with controls. The detection methods followed include Hematoxylin and Eosin (H&E) staining, immunohistochemistry, western blotting and real-time reverse transcription-polymerase chain reaction (RT-PCR). MCT induced pulmonary hypertension, pulmonary vascular remodeling, and right ventricular hypertrophy significantly increased the expressions of S100A4 and RAGE in the pulmonary arteries, lungs and right ventricle (RV). Fluoxetine dose-dependently inhibited MCT-induced pulmonary arterial hypertension, pulmonary vascular remodeling, and right ventricular hypertrophy and reduced the S100A4 and RAGE. Further analysis revealed that fluoxetine alleviated both the increase of p53, MMP13, MMP2 and MMP9 and the decrease of pp53Ser15 and MDM2 in lungs and RV tissues of MCT-induced PAH rats. From the present investigation it could be concluded that S100A4/Mts1 and its associated proteins are involved in the evolution of MCT-induced PAH in rats and fluoxetine inhibits MCT-induced PAH in rats mainly through S100A4/RAGE signaling axis and involved factors.
- 1 February 2018
- Published by Elsevier in Journal of Genetics and Genomics
- Vol. 45 (2) , 111-120
AQR is a novel type 2 diabetes-associated gene that regulates signaling pathways critical for glucose metabolism
- 1 February 2018
- Published by Elsevier in Journal of Genetics and Genomics
- Vol. 45 (2) , 111-120
AQR is a novel type 2 diabetes-associated gene that regulates signaling pathways critical for glucose metabolism
- Open Access
- 18 August 2012
- Published by Wiley in Basic & Clinical Pharmacology & Toxicology
- Vol. 112 (2) , 77-82
Fluoxetine Attenuates Chronic Methamphetamine‐induced Pulmonary Arterial Remodelling: Possible Involvement of Serotonin Transporter and Serotonin 1B Receptor
Epidemiological data have shown that methamphetamine (MA) abuse significantly increases the risk of developing pulmonary arterial hypertension (PAH). To investigate whether MA could induce PAH and its possible mechanism, rats were exposed daily to MA for 5 weeks in the absence or presence of fluoxetine. The results showed that the pulmonary arterial pressure was not significantly increased, but the pulmonary arterial remodelling was markedly developed in the MA exposure group. The protein expressions of the serotonin transporter (5‐HTT) and 5‐HT1B receptor were increased in the lungs and in the pulmonary arteries of MA‐treated rats. Fluoxetine attenuated the pulmonary arterial remodelling and down‐regulated the protein expression of 5‐HTT and 5‐HT1B receptor in pulmonary arteries of MA‐treated rats. These findings suggest that fluoxetine has a novel potential suppressive effect on the chronic MA‐induced pulmonary vascular remodelling and also suggest that 5‐HTT and 5‐HT1B receptor may be involved as part of its mechanism.
- 18 August 2012
- Published by Wiley in Basic & Clinical Pharmacology & Toxicology
- Vol. 112 (2) , 77-82
Open AccessFluoxetine Attenuates Chronic Methamphetamine‐induced Pulmonary Arterial Remodelling: Possible Involvement of Serotonin Transporter and Serotonin 1B Receptor
Epidemiological data have shown that methamphetamine (MA) abuse significantly increases the risk of developing pulmonary arterial hypertension (PAH). To investigate whether MA could induce PAH and its possible mechanism, rats were exposed daily to MA for 5 weeks in the absence or presence of fluoxetine. The results showed that the pulmonary arterial pressure was not significantly increased, but the pulmonary arterial remodelling was markedly developed in the MA exposure group. The protein expressions of the serotonin transporter (5‐HTT) and 5‐HT1B receptor were increased in the lungs and in the pulmonary arteries of MA‐treated rats. Fluoxetine attenuated the pulmonary arterial remodelling and down‐regulated the protein expression of 5‐HTT and 5‐HT1B receptor in pulmonary arteries of MA‐treated rats. These findings suggest that fluoxetine has a novel potential suppressive effect on the chronic MA‐induced pulmonary vascular remodelling and also suggest that 5‐HTT and 5‐HT1B receptor may be involved as part of its mechanism.